Showing 3371-3380 of 5773 results for "".
- Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Noregen for Retinal Diseaseshttps://modernod.com/news/caeregen-therapeutics-receives-14-million-phase-2-sbir-grant-from-nihnei-to-advance-development-of-regenerative-medicine-clinical-candidate-ctr-107-noregen-for-retinal-diseases/2481729/Caeregen Therapeutics announced that it has been awarded a $1.4 million phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen), a regenerative therapeutic for the treatme
- Glaukos Enters into a Collaboration and Marketing Agreement with Radius XRhttps://modernod.com/news/glaukos-enters-into-a-collaboration-and-marketing-agreement-with-radius-xr/2481728/Glaukos announced that it has entered into a collaboration and marketing agreement with Radius XR, whereby Glaukos will become the exclusive sales agent to market, promote, and solicit orders for the Radius XR wearable patient engagement and diagnostic system within the United States. Radius
- New Study Shows Zepto Precision Pulse Capsulotomy Safeguards Endothelial Cells as Effectively as Manual Capsulorhexishttps://modernod.com/news/new-study-shows-zepto-precision-pulse-capsulotomy-safeguards-endothelial-cells-as-effectively-as-manual-capsulorhexis/2481724/Centricity Vision announced that a
- Medical Consulting Group and Corcoran Consulting Group Finalize Merger Agreementhttps://modernod.com/news/medical-consulting-group-and-corcoran-consulting-group-finalize-merger-agreement/2481723/Medical Consulting Group (MCG) and Corcoran Consulting Group (CCG) have finalized their merger that was announced in April. Financial terms of the deal were not disclosed. MCG and CCG stated they believe this merger will enhance the ophthalmic community by providing
- Astellas Enters License Agreement with 4D Molecular Therapeutics to Use Intravitreal R100 Vector for Rare Ophthalmic Targetshttps://modernod.com/news/astellas-enters-license-agreement-with-4d-molecular-therapeutics-4dmt-to-use-proprietary-intravitreal-r100-vector-for-rare-ophthalmic-targets/2481721/Astellas Pharma and 4D Molecular Therapeutics announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one genetic target implicated in rare monogenic o
- Tenpoint Therapeutics Launches with Goal of Reversing Vision Loss Through Engineered Cell-Based Therapeuticshttps://modernod.com/news/tenpoint-therapeutics-launches-with-goal-of-reversing-vision-loss-through-engineered-cell-based-therapeutics-and-in-vivo-reprogramming/2481720/Tenpoint Therapeutics announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions. Tenpoint was established based on the work of its scientific founders from Mo
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- Allotex Secures Funding for Allogeneic Presbyopia Inlayshttps://modernod.com/news/allotex-secures-funding-for-allogeneic-presbyopia-inlays/2481717/Allotex and SpA announced the first close of its $30 million Series B financing to support the further development of its technology for the treatment of refractive errors. The investment was driven by 4-year data on presbyopia and hyperopia treatments, confirming significant impro
- Jay S. Duker, MD, Named President and CEO of Eyepoint Pharmaceuticalshttps://modernod.com/news/jay-s-duker-md-named-ceo-of-eyepoint-pharmaceuticals/2481715/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as President and Chief Executive Officer. Dr. Duker has transitioned from his most recent role as Chief Operating Officer (COO) and President. Dr. Duker has also been appointed to the Board of Di
- Cognition Therapeutics Doses First Patient in MAGNIFY Study of Oral CT1812 for GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-dosing-of-first-patient-in-magnify-study-of-oral-ct1812-for-ga-secondary-to-dry-amd/2481714/Cognition Therapeutics announced that it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The MAGNIFY study (COG2201,